Allogene Therapeutics, Inc. Stock price

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.47 USD +0.22% Intraday chart for Allogene Therapeutics, Inc. +2.05% +39.25%
Sales 2024 * 42.75K Sales 2025 * 4.12M Capitalization 754M
Net income 2024 * -283M Net income 2025 * -305M EV / Sales 2024 * 11,793 x
Net cash position 2024 * 250M Net cash position 2025 * 142M EV / Sales 2025 * 149 x
P/E ratio 2024 *
-2.67 x
P/E ratio 2025 *
-2.69 x
Employees 233
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.49%
More Fundamentals * Assessed data
Dynamic Chart
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index CI
Allogene Therapeutics Files $500 Million Mixed Shelf MT
Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops MT
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments MT
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023 CI
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating MT
Transcript : Allogene Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
North American Morning Briefing : Boeing Drags -2- DJ
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating MT
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic MT
Allogene Therapeutics Planning to Cut Roughly 22% of Workforce MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform MT
Allogene to cut 22% of its workforce RE
More news
1 day+0.22%
1 week+0.90%
Current month-8.96%
1 month-13.04%
3 months+39.69%
6 months+31.86%
Current year+39.25%
More quotes
1 week
4.14
Extreme 4.14
4.63
1 month
4.12
Extreme 4.12
5.78
Current year
2.61
Extreme 2.61
5.78
1 year
2.23
Extreme 2.23
6.89
3 years
2.23
Extreme 2.23
36.00
5 years
2.23
Extreme 2.23
55.00
10 years
2.23
Extreme 2.23
55.00
More quotes
Managers TitleAgeSince
Founder 47 17-10-31
Founder 64 18-03-31
Director of Finance/CFO 59 23-10-15
Members of the board TitleAgeSince
Director/Board Member 81 18-04-30
Founder 47 17-10-31
Founder 74 17-10-31
More insiders
Date Price Change Volume
24-03-28 4.47 +0.22% 1,377,673
24-03-27 4.46 +5.94% 1,897,214
24-03-26 4.21 -1.86% 1,281,475
24-03-25 4.29 +0.70% 1,259,937
24-03-22 4.26 -2.74% 1,507,687

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
4.47 USD
Average target price
11.66 USD
Spread / Average Target
+160.81%
Consensus
  1. Stock
  2. Equities
  3. Stock Allogene Therapeutics, Inc. - Nasdaq